NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis $31.73 0.00 (0.00%) As of 10/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Quince Therapeutics Stock (NASDAQ:QNCX) Get Quince Therapeutics alerts:Sign Up Key Stats Today's Range$31.73▼$31.7350-Day Range$26.72▼$32.0152-Week Range$15.10▼$909.98VolumeN/AAverage Volume31,090 shsMarket Capitalization$32.27 millionP/E RatioN/ADividend YieldN/APrice Target$189.88Consensus RatingModerate Buy Company Overview Quince Therapeutics is a biotechnology company focused on developing treatments for rare diseases. Its principal program has been EryDex, an investigational therapy designed to deliver dexamethasone sodium phosphate inside a patient’s own red blood cells. The company developed EryDex for ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological and immune-system problems. The treatment uses a process intended to load the drug into red blood cells for gradual release. Quince’s program followed its 2023 combination with EryDel, the company that developed the EryDex technology. EryDex was evaluated in a Phase 3 clinical trial, which did not meet its primary efficacy endpoint. Quince is headquartered in the United States; its work on EryDex grew out of technology developed by EryDel in Europe.AI Generated. May Contain Errors. Read More Quince Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreQNCX MarketRank™: 2.119078947365 of 5 starsQuince Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 647th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingQuince Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 2 strong buy ratings, 7 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialQuince Therapeutics has a consensus price target of $189.88, representing about 498.4% upside from its current price of $31.73.Amount of Analyst CoverageQuince Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quince Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Quince Therapeutics are expected to grow in the coming year, from ($8.39) to ($3.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for QNCX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuince Therapeutics does not currently pay a dividend.Dividend GrowthQuince Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quince Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.60% of the stock of Quince Therapeutics is held by insiders.Percentage Held by Institutions30.75% of the stock of Quince Therapeutics is held by institutions.Read more about Quince Therapeutics' insider trading history. Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Stock News HeadlinesQuince Therapeutics, Inc. (NASDAQ:QNCX) Stock Has Consensus Price Target of $189.88 According to AnalystsNovember 13 at 3:15 AM | americanbankingnews.comQuince Therapeutics (QNCX) Set to Release Quarterly Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 15 at 1:00 AM | Base Camp Trading (Ad)Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug DevelopmentOctober 9, 2026 | finance.yahoo.comQuince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary DiseaseOctober 9, 2026 | globenewswire.comQuince Shareholders Approve New Equity and Stock PlansOctober 6, 2026 | tipranks.comLeerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)October 1, 2026 | theglobeandmail.comQuince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome TranscriptSeptember 28, 2026 | seekingalpha.comSee More Headlines QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed this year? Quince Therapeutics' stock was trading at $670.00 on January 1st, 2026. Since then, QNCX stock has decreased by 95.3% and is now trading at $31.73. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) released its quarterly earnings data on Friday, August, 14th. The company reported ($12.31) EPS for the quarter, beating analysts' consensus estimates of ($28.02) by $15.71. When did Quince Therapeutics' stock split? Quince Therapeutics shares reverse split on the morning of Tuesday, June 30th 2026.The 1-20 reverse split was announced on Friday, June 26th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Quince Therapeutics IPO? Quince Therapeutics (QNCX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,412,000 shares at a price of $16.00-$18.00 per share. What other stocks do shareholders of Quince Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include NVIDIA (NVDA), Cassava Sciences (FLNA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Pfizer (PFE) and Ford Motor (F). Company Calendar Last Earnings8/14/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QNCX Previous SymbolNASDAQ:CRTX CIK1662774 Webwww.quincetx.com Phone(415) 910-5717FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Quince Therapeutics$189.88 High Price Target$1,000.00 Low Price Target$68.00 Potential Upside/Downside+498.4%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($156.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.98 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-133.84% Debt Debt-to-Equity RatioN/A Current Ratio14.52 Quick Ratio14.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($128.18) per share Price / Book-0.25Miscellaneous Outstanding Shares1,017,000Free Float960,000Market Cap$32.27 million OptionableNo Data Beta1.33 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:QNCX) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.